Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Renal Cell 64Neoplasm Metastasis 25Kidney Neoplasms 21Neoplasms 16Breast Neoplasms 15Carcinoma, Non-Small-Cell Lung 13Urinary Bladder Neoplasms 12Prostatic Neoplasms 10Lung Neoplasms 8Brain Neoplasms 8Melanoma 7Colorectal Neoplasms 7Pancreatic Neoplasms 6Ovarian Neoplasms 6Neuroendocrine Tumors 6Liver Neoplasms 6Glioblastoma 6Gastrointestinal Stromal Tumors 6Carcinoma, Hepatocellular 6Thyroid Neoplasms 5Thymoma 5Small Cell Lung Carcinoma 5Recurrence 5Multiple Myeloma 5Esophageal Neoplasms 5Carcinoma 5Uveal Melanoma 4Stomach Neoplasms 4Sarcoma 4Adenocarcinoma 4

Interventions

mirdametinib 2tipifarnib 1pirfenidone 1emvododstat 1cabozantinib 1binimetinib 1Sunitinib 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neurofibromatoses × Sunitinib × Clear all
NCT00589784 2016-01-25

Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
50 enrolled 6 charts
CNS

Brain Neoplasms, Meningioma, Neurofibromatosis 1, Neurofibromatosis 2, Central Nervous System Neoplasms, Neurofibromatoses, Hemangioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡